|
This is an index of reports of adverse events (side effects, adverse reactions, etc.) related to K-TAB (Potassium Chloride). Click on the relevant link below to view a selection of reports according to the event's seriousness level and/or the nature of the side effect / adverse reaction. Or scroll down to view all available reports.
Our database includes reports from Jan 2007 to Dec 2007. The information is not vetted and should not be cosidered as verified clinical evidence.
All cases (3)
Cases resulting in a serious event (3)
Cases resulting in death (2)
Cases resulting in life threatening events (1)
Cases resulting in hospitalization (3)
Cases resulting in other serious reactions (1)
Adverse event in 73 year old male receiving K-TAB (Potassium Chloride)
Reported by a physician from United States on 2007-04-26
Patient: 73 year old male
Adverse reactions / side effects: Mean Arterial Pressure Decreased, Dyspnoea, Hyperkalaemia, Atrioventricular Block Complete, Atrial Fibrillation, Bradycardia
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
K-TAB
Indication: Electrolyte Substitution Therapy
Start date: 2007-03-07
End date: 2007-03-29
Spironolactone
Indication: Cardiac Failure Congestive
Start date: 2006-05-14
End date: 2007-03-29
Dabigatran Etexilate
Indication: Drug USE FOR Unknown Indication
Other drugs received by patient: Bumetanide; Lisinopril
Adverse event in male receiving K-TAB (Potassium Chloride)
Reported by a physician from United States on 2007-03-05
Patient: male, weighing 71.2 kg (156.6 pounds)
Adverse reactions / side effects: Gallbladder Enlargement, Gastrointestinal Haemorrhage, Vomiting, Hypotension, Musculoskeletal Chest Pain, Chronic Obstructive Pulmonary Disease, Abdominal Pain Upper, Cardio-Respiratory Arrest, Abdominal Distension, Bradycardia, Asthenia, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Suspect drug(s):
K-TAB
Indication: Mineral Supplementation
Dabigatran Etexilate
Indication: Drug USE FOR Unknown Indication
Start date: 2004-10-11
End date: 2006-09-23
Dabigatran Etexilate
Start date: 2006-09-25
End date: 2006-09-27
Diovan
Indication: Hypertension
End date: 2006-09-27
Diltiazem Hydrochloride
Indication: Hypertension
End date: 2006-09-27
Amlodipine Besylate
Indication: Hypertension
End date: 2006-09-27
Other drugs received by patient: Glucophage; Prednisone; Atenolol; Atorvastatin; Naproxen Sodium; Torsemide
Adverse event in male receiving K-TAB (Potassium Chloride)
Reported by a physician from United States on 2007-02-23
Patient: male, weighing 71.2 kg (156.6 pounds)
Adverse reactions / side effects: Gallbladder Enlargement, Gastrointestinal Haemorrhage, Pneumonia, Vomiting, Hyperkalaemia, Hypotension, Musculoskeletal Chest Pain, Chronic Obstructive Pulmonary Disease, Abdominal Pain Upper, Gastrointestinal Ulcer, Cardio-Respiratory Arrest, Abdominal Distension, Bradycardia, Asthenia, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Suspect drug(s):
K-TAB
Indication: Mineral Supplementation
Dabigatran Etexilate
Indication: Drug USE FOR Unknown Indication
Start date: 2004-10-11
End date: 2006-09-23
Dabigatran Etexilate
Start date: 2006-09-25
End date: 2006-09-27
Diovan
Indication: Hypertension
End date: 2006-09-27
Diltiazem Hydrochloride
Indication: Hypertension
End date: 2006-09-27
Amlodipine Besylate
Indication: Hypertension
End date: 2006-09-27
Other drugs received by patient: Glucophage; Prednisone TAB; Atenolol; Atorvastatin; Naproxen Sodium; Torsemide
|
